On November 8, 2024, Nukkleus Inc. entered into a securities purchase agreement with NUKK TRACKER NOTES - CH1108678926 / 23714, a series of notes issued by ProETP DAC. The company sold 138,556 shares of its common stock at $1.7765 per share, raising aggregate gross proceeds of $246,145.The transaction was conducted as an unregistered sale of equity securities to an accredited investor. Nukkleus relied on exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D. No advertising or general solicitation was employed, and the transfer of common stock was restricted in accordance with Securities Act requirements.The company filed a Form 8-K on November 22, 2024, disclosing the transaction details. As an emerging growth company, Nukkleus has not elected to use the extended transition period for complying with new or revised financial accounting standards.

On November 8, 2024, Nukkleus Inc. entered into a securities purchase agreement with NUKK TRACKER NOTES - CH1108678926 / 23714, a series of notes issued by ProETP DAC. The company sold 138,556 shares of its common stock at $1.7765 per share, raising aggregate gross proceeds of $246,145.The transaction was conducted as an unregistered sale of equity securities to an accredited investor. Nukkleus relied on exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D. No advertising or general solicitation was employed, and the transfer of common stock was restricted in accordance with Securities Act requirements.The company filed a Form 8-K on November 22, 2024, disclosing the transaction details. As an emerging growth company, Nukkleus has not elected to use the extended transition period for complying with new or revised financial accounting standards.